Cytosorbents Corporation
CTSO
$0.59
$0.000.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.91% | 10.12% | 8.76% | -2.92% | 168.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.91% | 10.12% | 8.76% | -2.92% | 168.85% |
| Cost of Revenue | -16.09% | -16.03% | 19.84% | 19.08% | 297.18% |
| Gross Profit | 8.78% | 26.83% | 4.78% | -9.69% | 28.37% |
| SG&A Expenses | 20.94% | 3.06% | 7.17% | -9.17% | -30.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.31% | -8.96% | 6.61% | -7.56% | -7.89% |
| Operating Income | -9.25% | 43.72% | -1.26% | 16.52% | 64.87% |
| Income Before Tax | 40.62% | -29.01% | 145.34% | 75.72% | -25.31% |
| Income Tax Expenses | 100.00% | -- | -- | -- | -107.82% |
| Earnings from Continuing Operations | 27.36% | -14.52% | 145.34% | 75.72% | -15.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.36% | -14.52% | 145.34% | 75.72% | -15.10% |
| EBIT | -9.25% | 43.72% | -1.26% | 16.52% | 64.87% |
| EBITDA | -11.24% | 47.14% | -1.30% | 17.38% | 67.35% |
| EPS Basic | 36.73% | 0.59% | 139.32% | 78.28% | 2.05% |
| Normalized Basic EPS | 56.59% | -9.80% | 139.27% | 78.25% | 0.09% |
| EPS Diluted | 36.73% | 0.59% | 137.50% | 78.28% | 2.05% |
| Normalized Diluted EPS | 56.59% | -9.80% | 136.64% | 78.25% | 0.09% |
| Average Basic Shares Outstanding | 14.78% | 15.24% | 15.29% | 11.57% | 17.53% |
| Average Diluted Shares Outstanding | 14.78% | 15.24% | 23.68% | 11.57% | 17.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |